[go: up one dir, main page]

NO20051658L - Terapeutisk behandling - Google Patents

Terapeutisk behandling

Info

Publication number
NO20051658L
NO20051658L NO20051658A NO20051658A NO20051658L NO 20051658 L NO20051658 L NO 20051658L NO 20051658 A NO20051658 A NO 20051658A NO 20051658 A NO20051658 A NO 20051658A NO 20051658 L NO20051658 L NO 20051658L
Authority
NO
Norway
Prior art keywords
therapeutic treatment
pharmaceutically acceptable
acceptable salt
disclosed
combination
Prior art date
Application number
NO20051658A
Other languages
English (en)
Inventor
Francis Thomas Boyle
Jon Owen Curwen
David William Tonge
Sian Tomiko Taylor
Andrew Mark Hughes
Donna Johnstone
Neil James Gallagher
Ursula Joy Hancox
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20051658L publication Critical patent/NO20051658L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

2005-05-06 SAMMENDRAG Kombinasjon, omfattende en endotelin reseptorantagonist eller et farmasøytisk akseptabelt salt derav og en EGFR TKI eller et farmasøytisk 5. akseptabelt salt derav er beskrevet.
NO20051658A 2002-10-12 2005-04-04 Terapeutisk behandling NO20051658L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223854.1A GB0223854D0 (en) 2002-10-12 2002-10-12 Therapeutic treatment
PCT/GB2003/004347 WO2004035057A1 (en) 2002-10-12 2003-10-07 Therapeutic treatment

Publications (1)

Publication Number Publication Date
NO20051658L true NO20051658L (no) 2005-05-06

Family

ID=9945876

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051658A NO20051658L (no) 2002-10-12 2005-04-04 Terapeutisk behandling

Country Status (30)

Country Link
US (1) US20060122180A1 (no)
EP (1) EP1553950B1 (no)
JP (1) JP2006510605A (no)
KR (1) KR20050056238A (no)
CN (1) CN100342853C (no)
AR (1) AR041595A1 (no)
AT (1) ATE369136T1 (no)
AU (1) AU2003269259B2 (no)
BR (1) BR0315140A (no)
CA (1) CA2501959A1 (no)
CY (1) CY1107605T1 (no)
DE (1) DE60315490T2 (no)
DK (1) DK1553950T3 (no)
ES (1) ES2289316T3 (no)
GB (1) GB0223854D0 (no)
HK (1) HK1078784A1 (no)
IS (1) IS2473B (no)
MX (1) MXPA05003808A (no)
MY (1) MY135441A (no)
NO (1) NO20051658L (no)
NZ (1) NZ539137A (no)
PL (1) PL375584A1 (no)
PT (1) PT1553950E (no)
RU (1) RU2005114487A (no)
SA (1) SA04240502B1 (no)
TW (1) TW200412971A (no)
UA (1) UA82492C2 (no)
UY (1) UY28017A1 (no)
WO (1) WO2004035057A1 (no)
ZA (1) ZA200502874B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CA2701385A1 (en) * 2007-10-12 2009-04-16 Astrazeneca Ab Composition 064
JP2013501791A (ja) * 2009-08-10 2013-01-17 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム エンドセリン受容体の阻害剤による星状細胞−腫瘍細胞の処置
AU2019206652B2 (en) 2018-01-12 2024-11-14 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
US20220265628A1 (en) * 2019-07-17 2022-08-25 Enb Therapeutics, Inc. Treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists
TW202317555A (zh) 2021-06-22 2023-05-01 日商亞克醫藥股份有限公司 化合物、內皮素a受體拮抗劑及醫藥組合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
MEP42008A (en) * 1998-04-29 2011-02-10 Osi Farmaceuticals Inc N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen

Also Published As

Publication number Publication date
CY1107605T1 (el) 2013-03-13
GB0223854D0 (en) 2002-11-20
ZA200502874B (en) 2006-02-22
US20060122180A1 (en) 2006-06-08
EP1553950A1 (en) 2005-07-20
UY28017A1 (es) 2004-04-30
NZ539137A (en) 2008-01-31
DK1553950T3 (da) 2007-10-15
PT1553950E (pt) 2007-09-26
IS2473B (is) 2008-12-15
MY135441A (en) 2008-04-30
AU2003269259B2 (en) 2007-03-15
TW200412971A (en) 2004-08-01
DE60315490D1 (de) 2007-09-20
BR0315140A (pt) 2005-08-16
ES2289316T3 (es) 2008-02-01
DE60315490T2 (de) 2008-05-08
SA04240502B1 (ar) 2008-09-14
RU2005114487A (ru) 2006-02-10
ATE369136T1 (de) 2007-08-15
KR20050056238A (ko) 2005-06-14
CN1703224A (zh) 2005-11-30
AU2003269259A1 (en) 2004-05-04
MXPA05003808A (es) 2005-06-08
AR041595A1 (es) 2005-05-26
UA82492C2 (uk) 2008-04-25
JP2006510605A (ja) 2006-03-30
CA2501959A1 (en) 2004-04-29
HK1078784A1 (en) 2006-03-24
PL375584A1 (en) 2005-11-28
EP1553950B1 (en) 2007-08-08
IS7825A (is) 2005-04-26
CN100342853C (zh) 2007-10-17
WO2004035057A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
CY1109119T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
CY1107605T1 (el) Θεραπευτικη αγωγη
NO2013007I2 (no) Dapagliflozin og farmasøytisk akseptable salter derav
NO20030596L (no) Benzimidazolderivater, deres fremstilling og terapeutiske anvendelse
DE69814394D1 (de) Verwendung von levobupivacain
DK1513835T3 (da) Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1161434T3 (da) Pyridopyranoazepinderivater, deres fremstilling og terapeutiske anvendelse
IS2259B (is) Aðferð til meðferðar á netjuhersli með notkun mótlyfs við integríninu alfa-4 undireiningunni
MY137620A (en) Therapeutic treatment
NO20051892L (no) Ny forbindelse
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
NO20051893L (no) Ny forbindelse
PT1525193E (pt) Derivados do acilaminotiazole e sua utilização como inibidores de beta amilóide
DK1556382T3 (da) 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
CY1109001T1 (el) Οι καππα-οπιοιδεις αγωνιστες στη θεραπεια των παθησεων της κυστης
AR032422A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca
ATE325115T1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
MY136976A (en) Novel use of (r)-(-)-2-[5-(4- flourophenyl) -3-pyridylmethylaminomethyl]- chromane and its physiologically acceptable salts
IS2487B (is) Asýloxýpýrrólidín afleiður, framleiðsla og meðferðarnotkun þar á
AR038208A1 (es) Composicion farmaceutica dispersable oralmente de mitiglinida
NO20022482D0 (no) 2-arylkinolinderivater, fremgangsmåte og terapeutisk anvendelse derav
NO993546L (no) 1,4-dihydropyridinderivater og deres anvendelse i terapi
ITMI20022594A1 (it) Combinazione terapeutica per la cura dell'ipertensione.
DK1309594T3 (da) Benzimidazolderivater, fremstilling heraf og terapeutisk anvendelse heraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application